Taipei, Taiwan – November 25, 2025 – At the 8th Asian–Oceanian Congress of Clinical Neurophysiology (AOCCN 2025) in Taipei, NaviFUS Corp. (6872) announced encouraging early clinical data showing that its neuronavigation-guided focused ultrasound (FUS) system is expanding beyond epilepsy into the field of stroke rehabilitation.
Genovate Biotechnology and NaviFUS Corporation have completed the first cohort of an investigator-initiated pilot study at Alfred Hospital in Australia, using the NaviFUS neuronavigation-guided focused ultrasound system in patients with drug-resistant epilepsy (DRE).
An independent Safety Monitoring Committee confirmed a favorable safety profile with no major safety concerns and recommended moving to the next cohort with additional treatment sessions.
Early results are encouraging, with most participants showing fewer seizure days and lower seizure frequency, including some with >80% reduction from baseline.
NaviFUS Corps. (6872) announced that the U.S. clinical trial of its NaviFUS® focused ultrasound system for drug-resistant epilepsy (DRE), led by Stanford University successfully completed treatment of its first patient at the middle of Aug. The trial is expected to finish enrollment of all six participants in the first half of next year.
Key Points:
-The study is testing NaviFUS’s neuronavigation-guided focused ultrasound system for treating patients with drug-resistant epilepsy.
-Up to 18 participants will be treated in Melbourne.
NaviFUS Corp. is revolutionizing brain disorder treatments through ultrasound-based solutions, leveraging Taiwan’s advanced chip technology. By integrating ICT capabilities into high-end medical devices, NaviFUS enhances signal processing beyond traditional medical devices, positioning itself as a global leader in focused ultrasound treatments.
